Tick-Borne Disease Research Program Therapeutic/Diagnostic Research Award
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The Tick-Borne Disease Research Program Therapeutic/Diagnostic Research Award for fiscal year 2026 aims to fund innovative research focused on developing new treatments and diagnostic tools for Lyme disease and other tick-borne diseases. The program prioritizes early-stage therapeutic evaluation studies that explore novel drug or treatment options and diagnostic methods that can be easily implemented in clinical settings. The goal is to reduce disease burden and enhance patient care and quality of life through product-driven research initiatives. Administered by the Department of the Army under the Department of Defense, this award supports projects that address critical gaps in current approaches to tick-borne diseases by fostering the advancement of promising therapies and diagnostic technologies. Researchers interested in this opportunity can direct inquiries to the eBRAP Help Desk, and additional information is available through official grant portals. The program emphasizes translational research with the potential for real-world clinical application and impact.
General Info
Agency
NAICS
Place of Performance
Not specifiedSet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
Summary: The intent of the fiscal year 2026 (FY26) Tick-Borne Disease Research Program (TBDRP) Therapeutic/Diagnostic Research Award (TDRA) is to support product-driven therapeutic and diagnostic development research aimed at reducing the burden of Lyme disease and/or other tick-borne diseases and conditions, and improving patient care and/or quality of life. Treatment-focused applications should be therapeutic evaluation studies designed to advance new ideas aimed at drug or treatment discovery that are still in the early/preclinical stages of development. Diagnosis-focused applications should propose diagnostic approaches that will be readily integrated into clinical settings.
https://cdmrp.health.mil/pubs/press/2026/tbdrppreann
